- Conditions
- Advanced Solid Tumors
- Interventions
- AMG 305
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Duarte, California • Hackensack, New Jersey • New York, New York + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 67
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Recurrent Glioblastoma Multiforme(GBM)
- Interventions
- ACT001, ACT001 + Pembrolizumab
- Drug
- Lead sponsor
- Accendatech USA Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Malignant Solid Tumour, Renal Cell Carcinoma, Non Small Cell Lung Carcinoma
- Interventions
- Sorafenib, Vorinostat
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
- Interventions
- VLS-1488
- Drug
- Lead sponsor
- Volastra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more
- Conditions
- Glioblastoma or Malignant Glioma
- Interventions
- AMG 596, AMG 404
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New York, New York
- Conditions
- Advanced Non Small Cell Lung Cancer
- Interventions
- Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects), Part A - AZD9291 in combination with intermittent selumetinib, Part A - AZD9291 in combination with MEDI4736, Part B - AZD9291 in combination with AZD6094, Part B - AZD9291 in combination with selumetinib, Part B - AZD9291 in combination with MEDI4736, Part C - AZD6094 monotherapy (Japan only), Part C - AZD9291 in combination with AZD6094 (Japan only), Part D - AZD9291 in combination with AZD6094
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Cerebral Palsy
- Interventions
- Prone and Upright Locomotor Training
- Behavioral
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Up to 6 Weeks
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig, Rilvegostomig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Oakland, California + 18 more
- Conditions
- Infant, Premature, Diseases, Brain White Matter Disease Periventricular
- Interventions
- SPEEDI Intervention
- Behavioral
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- Up to 18 Weeks
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Suicide, Secure Firearm Storage
- Interventions
- Peer Engagement and Exploration of Responsibility and Safety, Active Control
- Behavioral · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- JZP898, Pembrolizumab
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 10
- States / cities
- Encinitas, California • Fresno, California • Denver, Colorado + 7 more
- Conditions
- Metastatic Castration-Resistant Prostatic Cancer
- Interventions
- TD001
- Drug
- Lead sponsor
- T.O.A.D. Oncology SA
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Advanced Solid Tumors
- Interventions
- AMG 994, AMG 404
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- Duarte, California • Detroit, Michigan • Cleveland, Ohio + 2 more
- Conditions
- Advanced Solid Tumors
- Interventions
- AMG 650
- Drug
- Lead sponsor
- Volastra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Santa Monica, California • Indianapolis, Indiana + 10 more
- Conditions
- Advanced Solid Tumors
- Interventions
- MEDI4736
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1,022 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 47
- States / cities
- Scottsdale, Arizona • Burbank, California • Gilroy, California + 41 more
- Conditions
- HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
- Interventions
- ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine
- Drug
- Lead sponsor
- Enliven Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Orlando, Florida • Plantation, Florida + 2 more
- Conditions
- Prostate Cancer
- Interventions
- AMG 509, Abiraterone, Enzalutamide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 479 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 25
- States / cities
- Duarte, California • Fullerton, California • San Francisco, California + 22 more
- Conditions
- Advanced Cancer, Metastatic Cancer, Solid Tumor, Melanoma, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Anaplastic Thyroid Cancer (ATC)
- Interventions
- JZP815
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Denver, Colorado • Orlando, Florida + 10 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Tarlatamab, AMG 404
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Lexington, Kentucky • Winston-Salem, North Carolina + 4 more
- Conditions
- Solid Tumors, Lymphoma
- Interventions
- ASTX660
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 23 more
- Conditions
- Metastatic Prostate Cancer
- Interventions
- JNJ-101556143 Formulation 1, JNJ-101556143 Formulation 2, JNJ-101556143 Formulation 3
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 17
- States / cities
- Colorado Springs, Colorado • Denver, Colorado • New Haven, Connecticut + 13 more
- Conditions
- Advanced Malignant Glioma, Anaplastic Astrocytomas, Glioblastoma Multiforme
- Interventions
- AMG 595
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Boston, Massachusetts • Cincinnati, Ohio
- Conditions
- Avoidant/Restrictive Food Intake Disorder
- Interventions
- Family-based Treatment for ARFID, Manualized Non-Specific Usual Care for ARFID
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Advanced Cancer
- Interventions
- LY2875358, LY2875358 + erlotinib, LY2875358 at Part A highest dose, LY2875358 at Part A highest dose + trametinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 10
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 7 more